Neurocrine Biosciences reported fourth‑quarter 2025 net product sales of $798.3 million, up 29% from $615.5 million a year earlier, and a full‑year total of $2.83 billion, a 22% increase over $2.36 billion in 2024. Non‑GAAP earnings per share were $1.88, falling short of the consensus range of $2.25 to $2.30 and marking a miss of roughly $0.37 to $0.42 per share. The company reiterated its 2026 guidance, projecting INGREZZA net product sales of $2.70 billion to $2.80 billion, a 10% growth from the current year’s $2.51 billion.
INGREZZA drove the bulk of the quarter’s performance, contributing $657.5 million in sales and $2.51 billion for the year. The drug’s volume growth was double‑digit, offset by pricing concessions tied to new formulary access investments that support long‑term market penetration. CRENESSITY, the newly launched treatment for classic congenital adrenal hyperplasia, added $135.3 million in Q4 sales and $301.2 million for the year, representing a 9% increase from the previous year’s $276.5 million and confirming the product’s rapid uptake in the U.S. market.
Operating margin remained robust at approximately 30% of net product sales, but the company noted that increased R&D and SG&A expenses—particularly those related to CRENESSITY’s launch and INGREZZA’s access program—put pressure on profitability. The EPS miss was largely attributable to these higher operating costs and the impact of pricing concessions, which reduced net price per unit even as volume expanded. Revenue beat some consensus estimates, but missed others that were based on higher price expectations, illustrating the trade‑off between volume growth and margin compression.
The company’s cash position grew to $2.54 billion at the end of 2025, up roughly $700 million from $1.84 billion in 2024, providing a strong financial cushion for continued investment in its pipeline. Management emphasized that the 2026 guidance reflects confidence in sustaining double‑digit volume growth for INGREZZA while maintaining a 10% increase in net product sales, and that the company remains focused on advancing Phase 3 programs in major depressive disorder and schizophrenia.
Market reaction to the earnings was mixed. Investors weighed the EPS miss against the revenue beat and the company’s conservative guidance, which some analysts viewed as cautious relative to a consensus of $3.41 billion for INGREZZA sales in 2026. The EPS miss underscored the impact of pricing concessions and higher operating expenses, while the guidance signals management’s confidence in continued growth but also highlights the need to manage cost inflation and pricing headwinds in the coming year.
Overall, the results reinforce Neurocrine’s strong commercial foundation and its ability to generate significant cash flow, but they also highlight the challenges of balancing volume expansion with margin preservation. The company’s pipeline remains a key driver of long‑term value, and the cash position provides flexibility to navigate the pricing and cost pressures that accompany the rollout of new products and the scaling of existing ones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.